NeoRx makes $7 million private placement

Article

Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent

Monoclonal antibody agent developer NeoRx has completed a privateplacement of equity to institutional investors in a deal worth$7 million to the Seattle-based firm. The company will use thefunds to pursue continued clinical trials of its Biostent andAvicidin therapy agents, according to president and CEO Dr. PaulAbrams.

NeoRx is awaiting final word from the Food and Drug Administrationon its Verluma agent for imaging small-cell lung cancer. An FDApanel recommended Verluma for approval in December (SCAN 12/27/95).NeoRx will receive $4.5 million from Verluma licensee Du PontMerck Pharmaceutical when the product is approved.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.